In summary, our findings align with existing literature, indicating EFV’s impact on prostate and bladder cancer treatment, likely attributed to its role in epigenetically repressing LINE-1 translation and activation of p53 tumor suppression protein. This evidence concerns the gene TP53 and urinary bladder carcinoma.